Drug Trial Radar · NCT01436994
Antithyroid Drug Treatment of Thyrotoxicosis in Young People
Last checked: Nov 20, 2026Latest source record: Sep 21, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
81
Actual
Start
Jul 2004
Primary completion
Dec 2014
Study completion Nov 2015
Sponsor
- Lead sponsor
- Newcastle-upon-Tyne Hospitals NHS TrustAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 20, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years, up to 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigators aim to establish whether biochemical control during anti-thyroid drug therapy in young people with thyrotoxicosis varies depending upon whether a 'block and replace' or 'dose titration' regimen is used. The investigators will also assess remission rates and the frequency of side-effects in the two treatment groups.
Conditions
- Paediatric Thyrotoxicosis
Interventions
Block and ReplaceProcedure
The primary objective of treatment is to maintain a euthyroid state with TSH and thyroid hormone levels in the local laboratory normal range. Carbimazole is commenced in a dose of 0.75 mg/kg/day (propylthiouracil - for dose see below) with the aim being to completely preventing endogenous thyroxine production. Thyroxine is then added in a low replacement dose as the thyroid hormone levels fall into the lower half of the laboratory normal range. The principle measure of control during the first 6 months will be thyroid hormone levels rather than TSH. Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil.
Dose TitrationProcedure
The primary objective of treatment is to maintain a euthyroid state with TSH and thyroid hormone levels in the local laboratory normal range. Carbimazole is commenced in a dose of 0.75 mg/kg/day until thyroid hormone levels fall into the local laboratory normal range. The dose is then reduced to 0.25 mg/kg/day with the intention of maintaining a euthyroid state as reflected by a free thyroxine and TSH within the normal range. Most paediatricians in the UK commence thyrotoxic children on carbimazole rather than propylthiouracil. Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. The guidelines detailed above can be used in the knowledge that 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil.
carbimazoleDrug
Carbimazole 5mg and 20 mg tablets Administered as a once or twice daily regimen with total daily dose adjusted according to prevailing biochemistry
propylthiouracilDrug
50 mg tablets administered once daily with the dose adjusted according to the prevailing biochemistry
thyroxineDrug
25mcg, 50mcg and 100mcg tabletes administered once daily with the dose adjusted according to the prevailing biochemistry
Primary outcomes
What the sponsor says the trial is designed to measure.
- Biochemical control as reflected by the stability of blood thyroid stimulating hormone (TSH) concentrationsTime frame: 2.5 years
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Royal Aberdeen Children's Hospital
Aberdeen, United Kingdom
Birmingham Children's Hospital
Birmingham, United Kingdom
Addebrookes Hospital
Cambridge, United Kingdom
Wales College of Medicine
Cardiff, United Kingdom
University Hospital
Coventry, United Kingdom
Ninewells Hospital
Dundee, United Kingdom
Royal Hospital for Sick Children
Edinburgh, United Kingdom
Royal Hospital for Sick Children
Glasgow, United Kingdom
Hereford Hospital
Hereford, United Kingdom
Crosshouse Hospital
Kilmarnock, United Kingdom
Alder Hey Children's Hospital
Liverpool, United Kingdom
St Bart's Hospital
London, United Kingdom
St George's Hospital
London, United Kingdom
Royal Manchester Children's Hospital
Manchester, United Kingdom
Royal Victoria Infirmary
Newcastle upon Tyne, United Kingdom
Norfolk & Norwich University Hospitals
Norwich, United Kingdom
Oxford Radcliffe Hospitals
Oxford, United Kingdom
Sheffield Children's Hospital
Sheffield, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.